Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 445

1.

Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases.

Nash RA, Dansey R, Storek J, Georges GE, Bowen JD, Holmberg LA, Kraft GH, Mayes MD, McDonagh KT, Chen CS, Dipersio J, Lemaistre CF, Pavletic S, Sullivan KM, Sunderhaus J, Furst DE, McSweeney PA.

Biol Blood Marrow Transplant. 2003 Sep;9(9):583-91.

2.

Epstein-Barr virus-related lymphoproliferative disorder induced by equine anti-thymocyte globulin therapy.

Viola GM, Zu Y, Baker KR, Aslam S.

Med Oncol. 2011 Dec;28(4):1604-8. doi: 10.1007/s12032-010-9635-8. Epub 2010 Aug 3.

PMID:
20680523
3.

Comparison of different rabbit ATG preparation effects on early lymphocyte subset recovery after allogeneic HSCT and its association with EBV-mediated PTLD.

Mensen A, Na IK, Häfer R, Meerbach A, Schlecht M, Pietschmann ML, Gruhn B.

J Cancer Res Clin Oncol. 2014 Nov;140(11):1971-80. doi: 10.1007/s00432-014-1742-z. Epub 2014 Jun 25.

PMID:
24962343
4.

High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts.

Hoegh-Petersen M, Goodyear D, Geddes MN, Liu S, Ugarte-Torres A, Liu Y, Walker JT, Fonseca K, Daly A, Duggan P, Stewart D, Russell JA, Storek J.

Bone Marrow Transplant. 2011 Aug;46(8):1104-12. doi: 10.1038/bmt.2010.272. Epub 2010 Nov 8.

PMID:
21057556
5.

Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation.

Blaes AH, Cao Q, Wagner JE, Young JA, Weisdorf DJ, Brunstein CG.

Biol Blood Marrow Transplant. 2010 Feb;16(2):287-91. doi: 10.1016/j.bbmt.2009.10.008. Epub 2009 Oct 14.

6.
7.

High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis.

Nash RA, Bowen JD, McSweeney PA, Pavletic SZ, Maravilla KR, Park MS, Storek J, Sullivan KM, Al-Omaishi J, Corboy JR, DiPersio J, Georges GE, Gooley TA, Holmberg LA, LeMaistre CF, Ryan K, Openshaw H, Sunderhaus J, Storb R, Zunt J, Kraft GH.

Blood. 2003 Oct 1;102(7):2364-72. Epub 2003 May 22.

8.

Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation.

Burt RK, Traynor AE, Pope R, Schroeder J, Cohen B, Karlin KH, Lobeck L, Goolsby C, Rowlings P, Davis FA, Stefoski D, Terry C, Keever-Taylor C, Rosen S, Vesole D, Fishman M, Brush M, Mujias S, Villa M, Burns WH.

Blood. 1998 Nov 15;92(10):3505-14.

9.

Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation.

Coppoletta S, Tedone E, Galano B, Soracco M, Raiola AM, Lamparelli T, Gualandi F, Bregante S, Ibatici A, di Grazia C, Dominietto A, Varaldo R, Bruno B, Frassoni F, Van Lint MT, Bacigalupo A.

Biol Blood Marrow Transplant. 2011 Jun;17(6):901-7. doi: 10.1016/j.bbmt.2010.10.003. Epub 2010 Oct 13.

10.

Epstein-Barr virus reactivation in a patient treated with anti-thymocyte globulin for severe aplastic anemia.

Calistri E, Tiribelli M, Battista M, Michelutti A, Corbellino M, Viale P, Fanin R, Damiani D.

Am J Hematol. 2006 May;81(5):355-7.

11.

High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment.

Juvonen E, Aalto SM, Tarkkanen J, Volin L, Mattila PS, Knuutila S, Ruutu T, Hedman K.

Bone Marrow Transplant. 2003 Jul;32(1):97-102.

PMID:
12815484
12.

Antithymocyte globulin pharmacokinetics in pediatric patients after hematopoietic stem cell transplantation.

Seidel MG, Fritsch G, Matthes-Martin S, Lawitschka A, Lion T, Pötschger U, Rosenmayr A, Fischer G, Gadner H, Peters C.

J Pediatr Hematol Oncol. 2005 Oct;27(10):532-6.

PMID:
16217256
13.

Epstein-Barr virus-associated post-transplant lymphoproliferative disorder presenting with skin involvement after CD34-selected autologous peripheral blood stem cell transplantation.

Takahashi S, Watanabe D, Miura K, Ozawa H, Tamada Y, Hara K, Matsumoto Y.

Eur J Dermatol. 2007 May-Jun;17(3):242-4. Epub 2007 May 4.

PMID:
17478388
14.

Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression.

Ellis D, Jaffe R, Green M, Janosky JJ, Lombardozzi-Lane S, Shapiro R, Scantlebury V, Vivas C, Jordan ML.

Transplantation. 1999 Oct 15;68(7):997-1003.

PMID:
10532541
15.

Post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation: a single-center experience.

Luo L, Zhang L, Cai B, Li H, Huang W, Jing Y, Zhu H, Zhao Y, Bo J, Wang Q, Han X, Yu L, Gao C.

Ann Transplant. 2014 Jan 8;19:6-12. doi: 10.12659/AOT.889683.

16.

Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.

Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl HB, Berger F, Hetzer R, Reinke P.

J Heart Lung Transplant. 2008 Jan;27(1):100-5. doi: 10.1016/j.healun.2007.09.027.

PMID:
18187094
17.

Fulminant Epstein-Barr virus (EBV)-associated T-cell lymphoproliferative disorder with hemophagocytosis following autologous peripheral blood stem cell transplantation for relapsed angioimmunoblastic T-cell lymphoma.

Awaya N, Adachi A, Mori T, Kamata H, Nakahara J, Yokoyama K, Yamada T, Kizaki M, Sakamoto M, Ikeda Y, Okamoto S.

Leuk Res. 2006 Aug;30(8):1059-62. Epub 2005 Dec 2.

PMID:
16330097
18.

Epstein-Barr virus-positive mucocutaneous ulcer arising in a post-hematopoietic cell transplant patient followed by polymorphic posttransplant lymphoproliferative disorder and cytomegalovirus colitis.

Satou A, Kohno A, Fukuyama R, Elsayed AA, Nakamura S.

Hum Pathol. 2017 Jan;59:147-151. doi: 10.1016/j.humpath.2016.08.001. Epub 2016 Aug 26.

PMID:
27569297
19.

[Clinical risks analysis of EBV infection in patients with allogeneic hematopoietic stem cell transplantation].

Bao X, Zhu Q, Qiu H, Chen F, Xue S, Ma X, Sun A, Wu D.

Zhonghua Xue Ye Xue Za Zhi. 2016 Feb;37(2):138-43. doi: 10.3760/cma.j.issn.0253-2727.2016.02.011. Chinese.

PMID:
27014984
20.

A case of EBV-associated lymphoproliferative disease following high-dose therapy and CD34-purified autologous peripheral blood progenitor cell transplantation.

Peniket AJ, Perry AR, Williams CD, MacMillan A, Watts MJ, Isaacson PG, Goldstone AH, Linch DC.

Bone Marrow Transplant. 1998 Aug;22(3):307-9.

Supplemental Content

Support Center